Offerings // Vir Biotechnology, Inc.

VIR offering history

Every offering-related filing in Vir Biotechnology, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 783 filings back to Jun 29, 2018.

Last executed offering

Feb 26, 2026

424B5 — priced deal (shares or notes)

Last registration (announced)

Nov 3, 2023

S-3ASR — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Feb 26, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Feb 24, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Feb 23, 2026	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Nov 3, 2023	S-3ASR →	REGISTERED	Automatic shelf registration — effective immediately (large filers)
Feb 19, 2021	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Nov 10, 2020	S-3ASR →	REGISTERED	Automatic shelf registration — effective immediately (large filers)
Jul 8, 2020	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Jul 7, 2020	S-1MEF →	REGISTERED	S-1MEF registration — capacity to sell shares, not a sale yet
Jul 7, 2020	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jul 6, 2020	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Apr 6, 2020	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Oct 11, 2019	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Oct 10, 2019	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Sep 30, 2019	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Sep 3, 2019	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet

VIR offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full VIR workspace →

VIR offering FAQ

When did VIR last execute an offering?

Per SEC filings, Vir Biotechnology, Inc.'s most recent priced offering document is a 424B5 filed 2026-02-26. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did VIR last announce or register an offering?

The most recent registration is a S-3ASR filed 2023-11-03. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.